Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Heath

Showing results (201-210 of 248) with videos related to

Pageof 25
Sort By:
The Oncologist|August 29, 2022
Comprehensive Genomic Profiling of Cell-Free DNA in Men With Advanced Prostate Cancer: Differences in Genomic Landscape Based on RaceRaquel Zimmerman, Mehmet A Bilen, Elisabeth I Heath, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 8, 2020
EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial CarcinomaJonathan Rosenberg, Srikala S Sridhar, Jingsong Zhang, et al.
The Journal of Clinical Investigation|April 23, 2024
Renal cell carcinoma histologic subtypes exhibit distinct transcriptional profilesPedro Barata, Shuchi Gulati, Andrew Elliott, et al.
Cancer Discovery|July 25, 2025
Off-pore nucleoporin sPOM121 transcriptionally propels β-Catenin driven tumor progression and immune escape in prostate cancerPerumalraja Kirthika, Vijayakumar Jawalagatti, Peiyao Li, et al.
Cancer Research Communications|January 28, 2025
Expression Patterns of DLL3 across Neuroendocrine and Non-neuroendocrine Neoplasms Reveal Broad Opportunities for Therapeutic TargetingJohn R Lozada, Andrew Elliott, Mark G Evans, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 8, 2015
SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate CancerEvan Y Yu, Hongli Li, Celestia S Higano, et al.
Frontiers in Oncology|October 3, 2022
Genomic landscape of advanced prostate cancer patients with <i>BRCA1</i> versus <i>BRCA2</i> mutations as detected by comprehensive genomic profiling of cell-free DNAUmang Swami, Raquel Mae Zimmerman, Roberto H Nussenzveig, et al.
The Journal of Clinical Investigation|July 15, 2024
Molecular analysis of primary and metastatic sites in patients with renal cell carcinomaShuchi Gulati, Pedro C Barata, Andrew Elliott, et al.
Journal of Pain and Symptom Management|May 5, 2025
Olanzapine for Managing Side Effects From Antiangiogenic Tyrosine-Kinase InhibitorsRegina M Koch, Miguel Muniz, Candy S Peskey, et al.
Cell|June 16, 2018
Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate CancerYi-Mi Wu, Marcin Cieślik, Robert J Lonigro, et al.
Pageof 25

Showing results (201-210 of 248) with videos related to

Sort By:
Pageof 25
The Oncologist|August 29, 2022
Comprehensive Genomic Profiling of Cell-Free DNA in Men With Advanced Prostate Cancer: Differences in Genomic Landscape Based on RaceRaquel Zimmerman, Mehmet A Bilen, Elisabeth I Heath, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 8, 2020
EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial CarcinomaJonathan Rosenberg, Srikala S Sridhar, Jingsong Zhang, et al.
The Journal of Clinical Investigation|April 23, 2024
Renal cell carcinoma histologic subtypes exhibit distinct transcriptional profilesPedro Barata, Shuchi Gulati, Andrew Elliott, et al.
Cancer Discovery|July 25, 2025
Off-pore nucleoporin sPOM121 transcriptionally propels β-Catenin driven tumor progression and immune escape in prostate cancerPerumalraja Kirthika, Vijayakumar Jawalagatti, Peiyao Li, et al.
Cancer Research Communications|January 28, 2025
Expression Patterns of DLL3 across Neuroendocrine and Non-neuroendocrine Neoplasms Reveal Broad Opportunities for Therapeutic TargetingJohn R Lozada, Andrew Elliott, Mark G Evans, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 8, 2015
SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate CancerEvan Y Yu, Hongli Li, Celestia S Higano, et al.
Frontiers in Oncology|October 3, 2022
Genomic landscape of advanced prostate cancer patients with <i>BRCA1</i> versus <i>BRCA2</i> mutations as detected by comprehensive genomic profiling of cell-free DNAUmang Swami, Raquel Mae Zimmerman, Roberto H Nussenzveig, et al.
The Journal of Clinical Investigation|July 15, 2024
Molecular analysis of primary and metastatic sites in patients with renal cell carcinomaShuchi Gulati, Pedro C Barata, Andrew Elliott, et al.
Journal of Pain and Symptom Management|May 5, 2025
Olanzapine for Managing Side Effects From Antiangiogenic Tyrosine-Kinase InhibitorsRegina M Koch, Miguel Muniz, Candy S Peskey, et al.
Cell|June 16, 2018
Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate CancerYi-Mi Wu, Marcin Cieślik, Robert J Lonigro, et al.
Pageof 25